Business Context and Reporting Period
OrthoPediatrics Corp. (Nasdaq: KIDS) filed a Form 8-K on April 1, 2020, reporting the completion of the acquisition of ApiFix Ltd., a private Israeli company. ApiFix develops and manufactures the ApiFix System, a minimally invasive deformity correction system for patients with Adolescent Idiopathic Scoliosis (AIS). The transaction was executed and closed on April 1, 2020.
Key Financial Metrics and Transaction Terms
This filing details a material definitive agreement and asset acquisition rather than periodic financial results. Key financial terms of the acquisition include:
- Closing Consideration: $2 million in cash plus 934,783 shares of OrthoPediatrics common stock. Based on the March 31, 2020 closing price of $39.64, the stock component was valued at approximately $37 million.
- Working Capital Adjustment: The purchase price is subject to a post-closing working capital adjustment.
- Contingent Anniversary Payments:
- Year 2: $13 million (accelerated if 150 U.S. clinical procedures are completed prior to the anniversary).
- Year 3: $8 million.
- Year 4: $9 million.
- System Sales Payment: Potential additional payment based on revenues from the ApiFix System for the twelve months ended June 30, 2024, multiplied by 2.25, to the extent it exceeds the Year 3 and Year 4 Anniversary Payments.
- Payment Form: Anniversary Payments and System Sales Payments may be made in cash and/or common stock, subject to limitations and specific determination rights.
Material Changes and Reduction Events
The filing outlines specific "Reduction Events" that could decrease the total purchase price by up to $15 million:
- Loss of FDA humanitarian device exemption or other regulatory approvals due to safety events.
- An implant failure rate exceeding 10% due to breakage.
Additionally, in the event of an "ApiFix Divestiture" (sale of majority IP or assets) on or before June 30, 2024, the remaining obligation is the higher of $45 million (less payments made) or the sum of the Year 2 payment and the System Sales Payment.
Guidance, Outlook, and Risks
Management indicated an intention to provide further details during a conference call on April 2, 2020. The filing includes a cautionary note regarding forward-looking statements, highlighting specific risks:
- COVID-19 Pandemic: Risks related to the impact of the pandemic on product demand and the Company's operational response.
- Regulatory and Safety: Risks associated with maintaining FDA exemptions and managing implant failure rates.
- Financial Statements: The Company intends to file required financial statements of the acquired business and pro forma financial information within 71 days of the filing date.
Investor Verification Checklist
- Verify the final closing share price used for the stock consideration calculation.
- Monitor the 71-day deadline for the filing of ApiFix's financial statements and pro forma information.
- Track the number of clinical procedures performed in the U.S. to determine if the Year 2 payment accelerates.
- Review future filings for any "Reduction Events" regarding FDA status or implant failure rates.
- Assess the impact of the $2 million immediate cash outflow on current liquidity.